Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus–pseudotype retroviral vector

HP Kiem(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), A. Dusty Miller(Harvard University), Greg Buron(Fred Hutch Cancer Center), Martin Göerner(Klinikum Bielefeld), Peter A. McSweeney(Mesoblast (United States)), J. Morris(Fred Hutch Cancer Center), R Storb(Fred Hutch Cancer Center), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Gene Therapy
June 1, 1999
10.1038/sj.gt.3300925
Cited by 41

Related Papers

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645